1. Home
  2. HYI vs RIGL Comparison

HYI vs RIGL Comparison

Compare HYI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HYI
  • RIGL
  • Stock Information
  • Founded
  • HYI 2010
  • RIGL 1996
  • Country
  • HYI United States
  • RIGL United States
  • Employees
  • HYI N/A
  • RIGL N/A
  • Industry
  • HYI Investment Managers
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HYI Finance
  • RIGL Health Care
  • Exchange
  • HYI Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • HYI 258.8M
  • RIGL 298.0M
  • IPO Year
  • HYI N/A
  • RIGL 2000
  • Fundamental
  • Price
  • HYI $11.41
  • RIGL $17.03
  • Analyst Decision
  • HYI
  • RIGL Buy
  • Analyst Count
  • HYI 0
  • RIGL 5
  • Target Price
  • HYI N/A
  • RIGL $36.80
  • AVG Volume (30 Days)
  • HYI 50.6K
  • RIGL 222.1K
  • Earning Date
  • HYI 01-01-0001
  • RIGL 05-06-2025
  • Dividend Yield
  • HYI 9.59%
  • RIGL N/A
  • EPS Growth
  • HYI N/A
  • RIGL N/A
  • EPS
  • HYI N/A
  • RIGL 0.99
  • Revenue
  • HYI N/A
  • RIGL $179,278,000.00
  • Revenue This Year
  • HYI N/A
  • RIGL $12.53
  • Revenue Next Year
  • HYI N/A
  • RIGL $15.68
  • P/E Ratio
  • HYI N/A
  • RIGL $17.36
  • Revenue Growth
  • HYI N/A
  • RIGL 54.71
  • 52 Week Low
  • HYI $10.99
  • RIGL $7.48
  • 52 Week High
  • HYI $12.24
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • HYI 38.09
  • RIGL 40.01
  • Support Level
  • HYI $11.15
  • RIGL $16.05
  • Resistance Level
  • HYI $11.63
  • RIGL $17.67
  • Average True Range (ATR)
  • HYI 0.19
  • RIGL 1.24
  • MACD
  • HYI 0.00
  • RIGL 0.03
  • Stochastic Oscillator
  • HYI 44.44
  • RIGL 39.46

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: